Roivant Sciences Ltd Investor Day Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Corinne Johnson - Goldman Sachs Group Inc - Analyst : Corinne Johnson, Goldman Sachs. Maybe on NIU, you mentioned that 50% of these patients have comorbid autoimmune disease. So what portion of the patients are kind of already on background JAK inhibitors? How are they treated in the trial? And what can we learn from their patient outcomes as you think about the mechanism of action?

Question: Corinne Johnson - Goldman Sachs Group Inc - Analyst : Maybe looking forward to that, you highlighted a combination program as well. And so as you think about a registrational program, how would you prioritize monotherapy versus combination? And how do you anticipate kind of this market playing out with respect to polypharmacy. And then kind of a last one to that. What do you need to show for this to be sort of the frontline treatment and background of therapy in PH-ILD?

Question: Corinne Johnson - Goldman Sachs Group Inc - Analyst : Corinne Johnson, Goldman Sachs. Maybe another big picture one in terms of commercial infrastructure, as you think building -- I think about building that out for multiple products across multiple launches. And what are some of the aspects of the commercial program you can leverage across these different products? And what do you have to build out distinctly? And as you think about like timing and team of bringing that on board.